Screener
Regeneron Pharmaceuticals REGN Equity Method Investments
Equity Method Investments at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount.
The source filing: Regeneron Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 6:52 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000872589-26-000025
- As of June 30, 2026 and December 31, 2025, $597.3 million and $334.0 million, respectively, of equity securities that do not have a readily determinable fair value. The change in carrying value of such investments was primarily the result of additional purchases.
- As of June 30, 2026 and December 31, 2025, equity and other securities held through ownership interest in an investment fund of $203.9 million and $147.5 million, respectively, which are primarily measured at fair value based on Level 3 inputs. The change in carrying value was primarily the result of additional purchases by the fund.
Item 1. Financial Statements (unaudited)
FAQ
- What is Regeneron Pharmaceuticals's equity method investments?
- Regeneron Pharmaceuticals (REGN) reported equity method investments of $597.3M in Q2 2026.
- What does equity method investments mean?
- Investments in unconsolidated affiliates and joint ventures where the company has significant influence (typically 20-50% ownership), carried at proportional book value.
Ask your AI about Regeneron Pharmaceuticals's equity method investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude